Document is current
Any future updates will be listed below
-
Authors
Simonsen, Johan R
Gordin, Daniel
Januszewski, Andrzej S
Jenkins, Alicia J
van Raalte, Daniël H
van Baar, Michael JB
Bjornstad, Petter
Thorn, Lena M
Groop, Per-Henrik
-
Funding
Funding for this research was provided by:
University of Helsinki
- License Information
-
More Information
Article History
Received: 21 August 2025
Accepted: 13 November 2025
First Online: 3 February 2026
Declarations
:
: The study was approved by the local ethics committee and conducted in accordance with the revised Declaration of Helsinki.
: All participants gave written informed consent.
: P-HG has received investigator-initiated grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, Astra Zeneca, Bayer, Boehringer-Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Nestlé, Novartis, Novo Nordisk, and Sanofi. He has received lecture honoraria from Astellas, Astra Zeneca, Bayer, Boehringer-Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, PeerVoice, Sanofi and Sciarc. DG lecture or Advisory Board Honoraria: Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius, GE Healthcare, Novo Nordisk. DHvR has acted as a consultant for and received honoraria from Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk and AstraZeneca and has received research operating funds from Boehringer Ingelheim, Eli Lilly, AstraZeneca, Merck and Novo Nordisk. All other authors: None.
